Skip to main content
SpringerLink
Log in

Antitumor Vaccines: Of Mice and Men?

  • Editorial
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7–17

    CAS  PubMed  Google Scholar 

  2. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639–48

    CAS  PubMed  Google Scholar 

  3. Mocellin S, Mandrzzato S, Bronte V, Lise M, Nitti D. Part I: vaccines for solid tumors. Lancet Oncol 2004;5:681–9

    Article  CAS  PubMed  Google Scholar 

  4. Dreno B, Nguyen JM, Khammari A, et al. Randomized trial of adoptive transfer of melanoma tumor-infiltrating lymphocytes as adjuvant therapy for stage III melanoma. Cancer Immunol Immunother 2002;51:539–46

    Google Scholar 

  5. Harris JE, Ryan L, Hoover HC Jr, et al. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J Clin Oncol 2000;18:148–57

    CAS  PubMed  Google Scholar 

  6. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19:2370–80

    Google Scholar 

  7. Mapura MY, Sykes M. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 2004;22:1136–51

    Article  PubMed  Google Scholar 

  8. Viehl CT, Becker-Hapak M, Lewis JS, et al. A Tat fusion protein-based tumor vaccine for breast cancer. Ann Surg Oncol (in press)

  9. Chazin VR, Kaleko M, Miller AD, Slamon DJ. Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. Oncogene 1992;7:1859–66

    CAS  PubMed  Google Scholar 

  10. Wadia JS, Dowdy SF. Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv Drug Deliv Rev 2005;57:579–96

    Article  CAS  PubMed  Google Scholar 

  11. Wilson NS, Villadangos JA. Regulation of antigen presentation and cross-presentation in the dendritic cell network: facts, hypothesis, and immunological implications. Adv Immunol 2005;86:241–305

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, New York University School of Medicine, 160 East 34th Street, NYU Clinical Cancer Center, Third Floor, New York, New York, 10016

    Kristin A. Skinner MD

Authors
  1. Kristin A. Skinner MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kristin A. Skinner MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Skinner, K.A. Antitumor Vaccines: Of Mice and Men?. Ann Surg Oncol 12, 511–512 (2005). https://doi.org/10.1245/ASO.2005.03.804

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/ASO.2005.03.804

Keywords

Search

Navigation